HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ETC-159

orally available PORCN, an endoplasmic reticulum resident enzyme that post-translationally palmitoleates

Also Known As:

ETC-1922159

Networked: 7 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - ETC-159: 7

Experts

1.	Madan, Babita: 2 articles (12/2019 - 10/2019)
2.	Virshup, David M: 2 articles (12/2019 - 10/2019)
3.	Arai, Seiji: 1 article (01/2022)
4.	Balk, Steven P: 1 article (01/2022)
5.	Bhasin, Manoj K: 1 article (01/2022)
6.	Calagua, Carla: 1 article (01/2022)
7.	Einstein, David J: 1 article (01/2022)
8.	Gu, Zhongkai: 1 article (01/2022)
9.	He, Meng Xiao: 1 article (01/2022)
10.	Liu, Yu: 1 article (01/2022)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2016 - "ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. "
2.	Necrosis 03/01/2023 - "ETC-159, an Upstream Wnt inhibitor, Induces Tumour Necrosis via Modulation of Angiogenesis in Osteosarcoma." 03/01/2023 - "Consistent with our hypothesis, we noted that ETC-159 treatment not only resulted in markedly decreased β-catenin staining in xenografts, but also increased tumour necrosis and a significant reduction in vascularity-a hereby yet undescribed phenotype following ETC-159 treatment. "
3.	Neoplasms (Cancer) 01/01/2022 - "IHC confirmed tumor cell WLS expression in primary prostate cancer and mCRPC, and patient-derived prostate cancer xenografts expressing WLS were responsive to treatment with Wnt synthesis inhibitor ETC-1922159. " 12/01/2019 - "We used deep time-resolved RNA-seq in two independent in vivo Wnt-addicted tumor models during treatment with the potent Wnt inhibitor ETC-159 and examined Wnt regulated splicing events and splicing regulators. " 10/01/2019 - "Importantly, multiple PI3K/mTOR pathway inhibitors in combination with ETC-159 synergistically suppressed the growth of multiple Wnt-addicted cancer cell lines in soft agar. " 11/01/2021 - "Lorecivivint, Wnt inhibitor, for the treatment of knee Osteoarthritis and SM-04554, Wnt activator, for the treatment of androgenetic alopecia are currently under Phase III. Other molecules, LGK-974, RXC-004, ETC-159, CGX-1321, PRI-724, CWP-232291 and BC-2059 are also under different stages of clinical development for the treatment of cancer. " 09/01/2017 - "Porcupine (PORCN), RSPO3, WNT2B, FZD5, FZD10, ROR1, tankyrase and β-catenin are targets of anti-WNT signaling therapy, and ETC-159, LGK974, OMP-18R5 (vantictumab), OMP-54F28 (ipafricept), OMP-131R10 (rosmantuzumab), PRI-724 and UC-961 (cirmtuzumab) are in clinical trials for cancer patients. "
4.	Knee Osteoarthritis 11/01/2021 - "Lorecivivint, Wnt inhibitor, for the treatment of knee Osteoarthritis and SM-04554, Wnt activator, for the treatment of androgenetic alopecia are currently under Phase III. Other molecules, LGK-974, RXC-004, ETC-159, CGX-1321, PRI-724, CWP-232291 and BC-2059 are also under different stages of clinical development for the treatment of cancer. "
5.	Osteosarcoma (Osteogenic Sarcoma) 03/01/2023 - "ETC-159, an Upstream Wnt inhibitor, Induces Tumour Necrosis via Modulation of Angiogenesis in Osteosarcoma."

Related Drugs and Biologics

1.	Catenins
2.	LGK974
3.	ICG 001
4.	Tankyrases
5.	RNA (Ribonucleic Acid)
6.	Agar
7.	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidine
8.	lorecivivint

Related Therapies and Procedures

1.	Therapeutics